ArticleCureus2025
Balancing the Treatment of Kaposi Sarcoma and Bullous Pemphigoid: A Therapeutic Challenge in a 63-Year-Old Male.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kaposi sarcoma is a malignancy evolving from the lining of blood and lymphatic vessels. It is caused by the reactivation of human herpesvirus 8, often due to underlying immunosuppression. Classic Kaposi sarcoma occurs in Eastern European males greater than 50 years of age as painless violaceous papules to nodules. We report a case of a 63-year-old man with severe Kaposi sarcoma first diagnosed on the right medial foot with progressive involvement of upper and lower extremities. It was managed with monthly rounds of excisional cauterization, electrodesiccation, cryotherapy, and 5% imiquimod topical cream, leading to overall improvement and avoidance of amputation. However, a year later the patient presented with bullous pemphigoid on the left distal upper arm, suprapubic skin, and right and left pretibial regions. After three months of treatment with mycophenolate mofetil, prednisone, triamcinolone, doxycycline, and clobetasol, the patient's bullous pemphigoid stabilized. Hence, the simultaneous presentation of bullous pemphigoid and Kaposi sarcoma displays a unique problem in the management and treatment of dermatological conditions. Kaposi sarcoma is exacerbated through immunosuppression, whereas bullous pemphigoid treatment requires immunosuppressants. Extensive excisional therapy and cryotherapy for Kaposi sarcoma, alongside careful management of immunosuppressants for bullous pemphigoid, is critical for managing optimal care in concurrent cases. Further research should be performed to better understand the causal interplay of Kaposi sarcoma, imiquimod, bullous pemphigoid, and other dermatological issues requiring immunosuppressant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.